Serum Lipoprotein (A) in Patients with Fibromyalgia Syndrome

Background: Fibromyalgia syndrome (FMS) is the most common rheumatic cause of diffuse pain and multiple regional musculoskeletal pain and disability. Objective: is to assess the contribution of serum lipoprotein (A) in the pathogenesis of FMS patients. Methods: One hundred twenty two FMS patients w...

Full description

Bibliographic Details
Main Authors: Mohammed * Hadi Munshed, Faiq Isho Gorial, Kismat M. Turki, Lubna Mahmood H.Farid
Format: Article
Language:English
Published: University of Baghdad/ Al-Kindy College of Medicine 2011-06-01
Series:مجله كليه طب الكندي
Subjects:
Online Access:https://jkmc.uobaghdad.edu.iq/index.php/MEDICAL/article/view/678
Description
Summary:Background: Fibromyalgia syndrome (FMS) is the most common rheumatic cause of diffuse pain and multiple regional musculoskeletal pain and disability. Objective: is to assess the contribution of serum lipoprotein (A) in the pathogenesis of FMS patients. Methods: One hundred twenty two FMS patients were compared with 60 healthy control individuals who were age and sex matched. All FMS features and criteria are applied for patients and controls; patients with secondary FMS were excluded. Serum Lipoprotein (A): [Lp(A)], body mass index (BMI), & s.lipid profile were determined for both groups. Results: There was a statistical significant difference between patients &controls in serum lipoprotein (A) (P=0.013). Also there was a statistical significant correlations between serum Lp(A) & FMS patients' age( r= 0.310, P=0.034 ); but not with: duration(r= - 0.222, P=0.133) , BMI(r= 0.128,P=0.390) & s.lipid profile ( p> 0.05) of FMS patients. Conclusion: s.lipoprotein (A) may play an important role in pathogenesis of FMS patients.
ISSN:1810-9543
2521-4365